Clinical Trial: Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236203) titled 'Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study' on May 25.

Brief Summary: This is a single-center real-world study aiming to explore predictive factors for the efficacy of CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Study Start Date: Feb. 29, 2024

Study Type: OBSERVATIONAL

Condition: Large B-Cell Lymphoma

Intervention: DRUG: CAR-T

CD19 CAR-T

Recruitment Status: RECRUITING

Sponsor: Fudan University

Information provided by (Responsible Party): Rong Tao, Fudan University

Published by HT Digital Content Services ...